RBD-Fc Vacc

An experimental COVID-19 subunit vaccine.

Phase of research

Potential treatment - pre-clinical evidence

How it helps


Drug status


Supporting references
Contradictory references
AI-suggested references
Clinical trials

General information

RBD-Fc Vacc is an experimental COVID-19 subunit vaccine prepared by a fusion of 2 SARS-CoV-2 Spike protein RBDs with a human IgG1 Fc. It is used adjuvanted with aluminum (Sun et al., 2021).


Supporting references

Link Tested on Impact factor Notes Publication date
Recombinant vaccine containing an RBD-Fc fusion induced protection against SARS-CoV-2 in nonhuman primates and mice
Spike protein Biophysical assay Animal model In vitro
in vitro binding assay; in vitro biophysical assay; hACE2-Tg mice; Macaca fascicularis macaques; SARS-CoV-2 adapted virus MASCp6; SARS-CoV-2 isolates BetaCoV/Beijing/IMEBJ01/2020, BetaCoV/Beijing/IMEBJ05/2020, and BetaCoV/Beijing/IMEBJ08/2020 8.48

The vaccine (in a 3-dose regimen) elicited RBD-specific antibody and neutralizing antibody responses (also against N501Y-carrying viral strain) in nonhuman primates. Humoral immune response was prevalent. In a viral challenge, vaccinated primates had lower viral RNA copy numbers. Analogical observations were made in a mouse model. In vaccinated primates, significantly reduced lung tissue pathology was noted after the viral challenge compared to the non-vaccinated ones.